FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Para fines de investigación únicamente. Aviso completo →

Investigación/Highlighting the risks associated with compounded GLP-1 receptor agonists and advocating for stringent safety standards.
Volver a Biblioteca de Investigación
GLP-1 receptor agonistsliraglutidesemaglutidetirzepatide

Highlighting the risks associated with compounded GLP-1 receptor agonists and advocating for stringent safety standards.

May 16, 2026
Share

Fuente del Paper

Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system.

McCall Kenneth L et al.Expert opinion on drug safety2026
Investigación Emergente

Basado en investigación emergente. Estos hallazgos son prometedores pero requieren validación adicional.

Sobre este análisis

Este artículo descompone los hallazgos del paper fuente anterior en lenguaje accesible para la comunidad de investigación de péptidos. Nuestro objetivo es destacar lo más importante — las implicaciones prácticas, la fuerza de la evidencia y lo que significa para la investigación en curso.

The Risks of Compounded GLP-1 Receptor Agonists: A Cautionary Tale

Published: May 16, 2026 | Source: Expert opinion on drug safety (2026) | Category: GLP-1 receptor agonists, liraglutide, semaglutide, tirzepatide

Overview

A recent study published in Expert Opinion on Drug Safety highlights the increased risks associated with compounded formulations of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), commonly used for diabetes and obesity management. The research underscores that these compounded drugs may pose higher safety concerns, including adverse events and medication errors, compared to FDA-approved products.

Study Background

Compounded GLP-1 RAs are not subject to the same rigorous testing as FDA-approved medications, raising questions about their safety and efficacy. This study aimed to evaluate the safety profile of compounded GLP-1 RAs by analyzing reports in the U.S. Food and Drug Administration's Adverse Event Reporting System (FAERS) from 2018 to 2024.

What the Research Found

The retrospective analysis of FAERS data revealed that out of 81,078 GLP-1 RA safety reports, 707 involved compounded products. Compounded formulations were associated with higher reporting odds ratios (RORs) for several adverse events:

  • Abdominal pain: ROR = 2.84
  • Diarrhea: ROR = 1.59
  • Nausea: ROR = 1.27
  • Suicidality: ROR = 6.34
  • Cholecystitis: ROR = 3.39

Additionally, compounded GLP-1 RAs were linked to a higher likelihood of medication errors and product quality issues:

  • Preparation errors: ROR = 48.92
  • Prescribing errors: ROR = 4.46
  • Contamination: ROR = 19.00
  • Compounding/manufacturing issues: ROR = 8.51

These findings suggest that compounded GLP-1 RAs may carry a higher risk of adverse events and safety concerns compared to FDA-approved products.

What This Means for Peptide Users

The study's results indicate that patients using compounded GLP-1 RAs might face an elevated risk of experiencing adverse effects, including gastrointestinal issues and psychological distress. Healthcare providers should exercise caution when prescribing these compounds and ensure rigorous quality control measures are in place. Patients should be informed about the potential risks associated with compounded formulations and consider FDA-approved alternatives if available.

Limitations and Caveats

While this study provides valuable insights into the safety profile of compounded GLP-1 RAs, it is important to acknowledge its limitations:

  • Retrospective Analysis: The findings are based on retrospective data from FAERS, which may be subject to reporting biases.
  • Lack of Randomized Controlled Trials (RCTs): Without RCTs, the study cannot definitively establish causality between compounded GLP-1 RAs and adverse events.

How This Compares to Previous Research

Previous studies have also highlighted safety concerns associated with compounded medications. However, this is one of the first comprehensive analyses focusing specifically on GLP-1 RAs. The findings align with broader literature suggesting that compounded drugs may pose unique risks due to variations in manufacturing processes and quality control.

Our Analysis

PeptideVault's analysis underscores the importance of this study for both healthcare providers and patients. While compounded medications can offer flexibility in treatment options, especially for rare conditions or personalized dosing requirements, the increased risk profile highlighted by this research should prompt a reevaluation of their use. The findings reinforce the need for stringent safety standards and enhanced monitoring mechanisms to protect patient health.

Key Takeaways

  • Higher Risk Profile: Compounded GLP-1 RAs are associated with higher odds of adverse events compared to FDA-approved products.
  • Quality Control Issues: These compounded drugs face a greater likelihood of preparation, prescribing, contamination, and manufacturing errors.
  • Patient Monitoring: Healthcare providers should closely monitor patients using compounded GLP-1 RAs for potential adverse effects.

Original Source

Citation: McCall Kenneth L, Mastro Dwyer Keri A, Casey Ryan T et al. (2026). Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system.. Expert opinion on drug safety. DOI: 10.1080/14740338.2025.2499670

Access:

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

Nota del Editor

Este análisis fue preparado por el equipo de investigación de Peptide Contacts. Se anima a los lectores a revisar la fuente completa del paper para metodología y datos completos. La publicación original está disponible en PubMed.

Investigación Relacionada

Comments

Sign in to join the discussion

Este análisis se genera a partir de investigación revisada por pares para fines educativos solo. No constituye consejo médico. Consulte siempre a un proveedor de atención médica calificado antes de usar cualquier terapia basada en péptidos.